MedTrace Logo

Magseed Pro(R)/ Sentimag(R) Gen3

NCT05142787 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2024-09-19

No results posted yet for this study

Summary

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast

Conditions

Interventions

DEVICE

Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics

placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions

Sponsors & Collaborators

  • Endomagnetics Ltd.

    lead INDUSTRY

Principal Investigators

  • Stefan Paepke, Dr · The technical university of Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142787 on ClinicalTrials.gov